Premier Alternatives

MitoRx Therapeutics

Oxford, United Kingdom · Founded 2021 · Privately Held (backing)

Developer of small molecule therapeutics designed for weight loss with muscle preservation in obesity-related and cardiometabolic conditions. MitoRx Therapeutics is based in Oxford, United Kingdom and was founded in 2021. Its last reported valuation was $31.4 million in Nov 2025. It has raised $17.5 million.

Last reported valuation
$31.4M
Oct 2026
Priced at
—
Total raised
$17.5M
Last round
—

MitoRx Therapeutics key facts

as of Oct 2026
  • Developer of small molecule therapeutics designed for weight loss with muscle preservation in obesity-related and cardiometabolic conditions.
  • MitoRx Therapeutics is valued at approximately $31.4M as of Oct 2026 (last reported valuation).
  • It has raised $17.5M; the latest was Early Stage VC ($9.6M) in Nov 2025.
  • Notable investors include Future Planet Capital, UK Innovation & Science Seed Fund, WCS Nominees, Empirical Ventures, The Betsy and Jesse Fink Family Foundation — 13 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$31.4M

MitoRx Therapeutics's last reported valuation, Nov 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of MitoRx Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch MitoRx Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

MitoRx Therapeutics funding rounds

No rounds on record

No funding rounds for MitoRx Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

MitoRx Therapeutics valuation

MitoRx Therapeutics's last reported valuation was $31.4 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.

MitoRx Therapeutics investors

13 investors are on record for MitoRx Therapeutics, including Future Planet Capital, UK Innovation & Science Seed Fund, WCS Nominees and Empirical Ventures.

About MitoRx Therapeutics

Developer of small molecule therapeutics designed for weight loss with muscle preservation in obesity-related and cardiometabolic conditions. The company is advancing mitochondrial-targeted persulfide modifiers that restore a signaling mechanism identified through population-based studies, with preclinical data demonstrating efficacy against hepatosteatosis, effectiveness as a monotherapy, and enhanced fat loss with lean mass gain when combined with glucagon-like peptide-1 receptor agonists, enabling biopharmaceutical developers and healthcare providers to access a foundational therapeutic modality that tackles underlying cellular dysfunction to potentially improve patient outcomes across a spectrum of metabolic and degenerative disorders.

Sector
Healthcare
HQ
Oxford, United Kingdom
Founded
2021
Employees
14
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.